Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | BAX | Q07812 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL10731360 | 0.92 | LTA4H (0.53) | LTA4HTSHRTRPA1ALDH1A1FFAR1 | |
| SCHEMBL5885219 | 0.90 | ST14 (0.48) | LTA4HTSHRTRPA1ALDH1A1FFAR1 | |
| SCHEMBL6177832 | 0.85 | HTT (0.62) | LTA4HTSHRTRPA1ALDH1A1FFAR1 | |
| SCHEMBL7456192 | 0.82 | TDP1 (0.62) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL2112963 | 0.82 | LTA4H (0.52) | LTA4HTSHRTRPA1ALDH1A1FFAR1 | |
| SCHEMBL202774 | 0.80 | ALDH1A1 (0.54) | LTA4HTSHRTRPA1ALDH1A1 | |
| SCHEMBL13932446 | 0.80 | KCNA3 (0.67) | LTA4HTSHRTRPA1ALDH1A1FFAR1 | |
| SCHEMBL23098203 | 0.80 | SRD5A2 (0.70) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL19322270 | 0.80 | LTA4H (0.67) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL9906839 | 0.80 | SRD5A2 (0.70) | LTA4HTSHRFFAR1SRD5A2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737450-A1 | HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE | Longwood Pharmaceuticals (Hangzhou) Co., Ltd (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4568958-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| CN-119698413-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119604497-A | Heteroaromatic carboxamides and their use in medicine | 远森制药（杭州）有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025001956-A1 | HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE | 远森制药（杭州）有限公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024033388-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| WO-1994027601-A1 | ALIPHATIC AMINO BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1993023373-A1 | N-[N'-(5-AMINO-4-HYDROXY-ACYLOYL)-α-AMINOACYLOYL] SUBSTITUTED HETEROCYCLES AND THEIR USE AS ANTIVIRAL AGENTS | PFIZER LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
| EP-0186190-B1 | BENZIMIDAZOLE DERIVATIVES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| US-4663339-A | Acaricidal and insecticidal substituted 1-phenylalkylbenzimidazoles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-05-05 | — | — | US | disclosed |
| US-4612323-A | Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-09-16 | — | — | US | disclosed |
| EP-0186190-A2 | Benzimidazole derivatives, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-07-02 | — | — | EP | disclosed |
| EP-0132606-A1 | Benzimidazole derivatives, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-02-13 | — | — | EP | disclosed |
| US-4335052-A | OXIDATION OF CORRESPONDING BENZYL HALIDE WITH TERITARY AMINE OXIDEIN PRESENCE OF WATER | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1982-06-15 | — | — | US | disclosed |
| US-4141921-A | INSECTICIDES | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | LTA4H 532/4885TSHR 4421/4885TRPA1 3765/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | LTA4H 2978/4885TSHR 756/4885TRPA1 1301/4885 |
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | SCN1B, SCN2B, SCN11A | LTA4H 2701/4885TSHR 420/4885TRPA1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.